.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The FOxTROT trial evaluated whether giving a short course of chemotherapy before surgery could improve outcomes for patients with operable, locally advanced colon cancer. More than 1,000 patients were randomized to either immediate surgery followed by standard postoperative treatment or a perioperative strategy that started systemic chemotherapy before surgery and continued after resection. The study showed that preoperative treatment could be delivered safely in appropriately selected patients and was associated with more favorable pathological tumor regression and a lower burden of residual or recurrent disease at early follow-up. Importantly, the approach did not replace surgery; it was designed to integrate systemic therapy into the surgical pathway so that treatment of micrometastatic disease could begin earlier. For surgeons and multidisciplinary teams, the practical message is that the timing of chemotherapy is becoming an important part of colon-cancer management rather than a fixed “surgery first” sequence. Patient selection, staging and multidisciplinary coordination remain critical because not every patient with colon cancer requires or benefits from the same perioperative strategy.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The FOxTROT trial evaluated whether giving a short course of chemotherapy before surgery could improve outcomes for patients with operable, locally advanced colon cancer. More than 1,000 patients were randomized to either immediate surgery followed by standard postoperative treatment or a perioperative strategy that started systemic chemotherapy before surgery and continued after resection. The study showed that preoperative treatment could be delivered safely in appropriately selected patients and was associated with more favorable pathological tumor regression and a lower burden of residual or recurrent disease at early follow-up. Importantly, the approach did not replace surgery; it was designed to integrate systemic therapy into the surgical pathway so that treatment of micrometastatic disease could begin earlier. For surgeons and multidisciplinary teams, the practical message is that the timing of chemotherapy is becoming an important part of colon-cancer management rather than a fixed “surgery first” sequence. Patient selection, staging and multidisciplinary coordination remain critical because not every patient with colon cancer requires or benefits from the same perioperative strategy.
4 weeks back
Discover how catalytic nanozymes redefine autoimmune disease therapy by establishing a physiological redox set-point to restore immune tolerance without broad immunosuppression.
Last week
Recent research reveals that downregulating YAP1/TAZ-TEAD via Hippo signaling triggers spontaneous human trophoblast syncytialization in 3D cultures, illuminating placental biology and preeclampsia.
3 weeks back
A landmark comparative study evaluates atrial electrophysiology across humans, swine, and rodents. By linking cellular recordings with transcriptomics and in silico modeling, researchers resolve cross-species gaps, explaining translational failures to advance targeted therapies for atrial arrhythmias.
3 weeks back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
last month
Researchers have developed an innovative ultrasound-responsive nano-contrast agent that co-delivers CIITA-siRNA and rapamycin directly to inflamed thyroid tissue, significantly reducing autoimmune injury and thyroid autoantibodies in preclinical models of Hashimoto thyroiditis.
3 weeks back
